We identified a novel GTPase, SLIP-GC, with expression limited to a few tissues, in particular germinal center B cells. It lacks homology to any known proteins, indicating that it may belong to a novel family of GTPases. SLIP-GC is expressed in germinal center B cells and in lymphomas derived from germinal center B cells such as large diffuse B cell lymphomas. In cell lines, SLIP-GC is expressed in lymphomas that express activation-induced deaminase (AID) and that likely undergo somatic hypermutation. SLIP-GC is a nuclear protein, and it localizes to replication factories. Reduction of SLIP-GC levels in the Burkitt lymphoma cell line Raji and in non-Hodgkin lymphoma cell lines resulted in an increase in DNA breaks and apoptosis that was AID-dependent, as simultaneous reduction of AID abrogated the deleterious effects of SLIP-GC reduction. These results strongly suggest that SLIP-GC is a replication-related protein in germinal center B cells whose reduction is toxic to cells through an AID-dependent mechanism.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2781619PMC
http://dx.doi.org/10.1074/jbc.M109.014506DOI Listing

Publication Analysis

Top Keywords

germinal center
24
center cells
20
slip-gc
8
slip-gc nuclear
8
slip-gc expressed
8
cell lines
8
reduction slip-gc
8
lymphoma cell
8
germinal
6
center
6

Similar Publications

Head and neck squamous cell carcinoma (HNSCC) is the seventh most common cancer worldwide with a poor prognosis for survival. Risk factors include alcohol and tobacco abuse and infection with human papilloma virus (HPV). To enhance anti-tumor immune responses immunotherapeutic approaches are approved for recurrent metastatic disease but only approx.

View Article and Find Full Text PDF

Function and Regulation of Age-Associated B Cells in Diseases.

J Cell Physiol

January 2025

Key Laboratory of Cell Proliferation and Regulation Biology, Ministry of Education, College of Life Sciences, Beijing Normal University, Beijing, China.

The aging process often leads to immune-related diseases, including infections, tumors, and autoimmune disorders. Recently, researchers identified a special subpopulation of B cells in elderly female mice that increases with age and accumulates prematurely in mouse models of autoimmune diseases or viral infections; these B cells are known as age-related B cells (ABCs). These cells possess distinctive cell surface phenotypes and transcriptional characteristics, and the cell population is widely recognized as CD11cCD11bT-betCD21CD23 cells.

View Article and Find Full Text PDF

BACKGROUND Simultaneously occuring diffuse large B-cell lymphoma (DLBCL) and Hodgkin lymphoma (HL) is extremely rare. Generally, patients with CD20-positive DLBCL receive rituximab, cyclophosphamide, vincristine, doxorubicin, prednisone (R-CHOP) regimen, while those with HL receive brentuximab vedotin, doxorubicin, vinblastine, dacarbazine (A-AVD) regimen as first-line therapy. Establishing a strategy for treating both lymphoma subtypes concurrently is thus very difficult.

View Article and Find Full Text PDF
Article Synopsis
  • The study evaluates various techniques for guiding percutaneous coronary intervention (PCI) to determine which yields the best patient outcomes.
  • It analyzes data from 39 randomized trials involving over 29,000 patients, highlighting that intravascular imaging (like OCT and IVUS) and physiology-guided strategies (like FFR) significantly reduce cardiac death compared to traditional coronary angiography (CA).
  • Overall, the results suggest that OCT is the most effective guidance method, leading to lower rates of myocardial infarction, stent thrombosis, and all-cause mortality compared to CA.
View Article and Find Full Text PDF
Article Synopsis
  • Current kidney transplant regimens often struggle to prevent antibody-mediated rejection (ABMR) in sensitized individuals, leading to graft failure.
  • Research showed that anti-CD154 monoclonal antibody (mAb) treatment for kidney transplants in nonhuman primates was more effective at controlling rejection and post-transplant immune responses than standard tacrolimus-based therapy.
  • The anti-CD154-treated group had significantly longer survival rates, better suppression of harmful antibodies, and fewer complications post-transplant, suggesting that anti-CD154 mAbs could enhance outcomes in sensitized kidney transplant patients.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!